Pharmacologic treatments for covid-19 patients

Interferon Beta vs Standard care/Placebo


Hospitalized patients

Forest plots
(last update: 2021-06-18)

Summary of findings
(last update: 2022-03-30)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=26

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04343768
COVIFERON
Darazam IA, Scientific Reports, 2021
Full text
Commentary
Commentary
No specific funding

INF beta-1b

INF beta-1a

INF beta-1b

INF beta-1b

Standard care

Standard care

INF beta-1a

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran. N=60
Some concerns
Details

Full description

ISRCTN83971151; NCT04315948
SOLIDARITY (IFN)
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed

INF beta-1a

Standard care

RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. N=4127
Low
Details

Full description

IRCT20100228003449N27
Rahmani H, Int Immunopharmacol, 2020
Full text
Commentary
No specific funding

INF beta-1b

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=80
Some concerns
Details

Full description

IRCT20100228003449N28
Davoudi-Monfared E, Antimicrob Agents Ch, 2020
Full text
Commentary
Private

INF beta-1a

Standard care

RCT Patients with COVID-19 (moderate to critical) admitted to a single center in Iran. N=92
High
Details

Full description